Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 7/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | IDH2 | P48735 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 2/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | FLT4 | P35916 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24773 | 1.00 | CTSC (0.44) | CTSCGRIN1GRIN2BERBB2EGFR | |
| SCHEMBL23924 | 0.91 | ERBB2 (0.47) | ERBB2EGFRSYKPRMT5 | |
| SCHEMBL24535 | 0.91 | ERBB2 (0.47) | ERBB2EGFRSYKPRMT5 | |
| SCHEMBL24110 | 0.88 | ALDH1A1 (0.51) | ERBB2EGFRPRMT5 | |
| SCHEMBL23474 | 0.88 | ALDH1A1 (0.51) | ERBB2EGFRPRMT5 | |
| SCHEMBL22927 | 0.86 | ERBB2 (0.48) | ERBB2EGFR | |
| SCHEMBL24431 | 0.86 | ERBB2 (0.48) | ERBB2EGFR | |
| SCHEMBL23189 | 0.83 | IDH2 (0.57) | CTSCIDH2FLT1FLT4KDR | |
| SCHEMBL24629 | 0.83 | IDH2 (0.57) | CTSCIDH2FLT1FLT4KDR | |
| SCHEMBL23997 | 0.83 | ERBB2 (0.44) | ERBB2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9023851-B2 | Triazolopyrazine derivatives | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | claimed |
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | claimed |
| US-9023851-B2 | Triazolopyrazine derivatives | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | disclosed |
| US-9023851-B2 | Triazolopyrazine derivatives | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | disclosed |
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | disclosed |
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | disclosed |
| WO-2012025186-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | SYK, IRAK1, ZAP70 | CTSC 1943/4885GRIN1 2315/4885GRIN2B 3735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.